Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status

Journal of Neuro-Oncology

Volumn 97, Issue 3, 2010, Pages 389-392

  Kurzwelly, Delia ^a   Glas, Martin ^a   Roth, Patrick ^b   Weimann, Elke ^c   Lohner, Hanns ^d   Waha, Andreas ^a   Schabet, Martin ^c   Reifenberger, Guido ^e   Weller, Michael ^b   Herrlinger, Ulrich ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c KLINIKUM LUDWIGSBURG   (Germany)

^d Klinikum Rosenheim   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Chemotherapy; MGMT; Primary central nervous system lymphoma; Temozolomide

Indexed keywords

GENOMIC DNA; METHOTREXATE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROCARBAZINE; RITUXIMAB; TEMOZOLOMIDE;

ADULT; AGE; AGED; ARTICLE; BLOOD TOXICITY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; COMORBIDITY; DISEASE SEVERITY; DNA METHYLATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; ERYTHEMA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGRESSION FREE SURVIVAL; PROMOTER REGION; RELAPSE; RETROSPECTIVE STUDY; SURVIVAL TIME; THROMBOCYTOPENIA; WHOLE BRAIN RADIOTHERAPY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CENTRAL NERVOUS SYSTEM NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GERIATRICS; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 77953285732     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-009-0032-0     Document Type: Article

References (13)

1. Jahnke K, Korfel A, Martus P, Weller M, Herrlinger U, Schmittel A, Fischer L, Thiel E, German Primary Central Nervous System Lymphoma Study Group (G-PCNSL-SG) (2005) High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. Ann Oncol 16:445-449 (Pubitemid 40458322)
2. Nelson DF, Martz KL, Bonner H, Nelson JS, Newall J, Kerman HD, Thomson JW, Murray KJ (1992) Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 23:9-17
3. Reni M, Mason W, Zaja F, Perry J, Franceschi E, Bernardi D, Dell'Oro S, Stelitano C, Candela M, Abbadessa A, Pace A, Bordonaro R, Latte G, Villa E, Ferreri AJ (2004) Salvage chemotherapy with temozolomide in primary CNS lymphomas: preliminary results of a phase II trial. Eur J Cancer 40:1682-1688
4. Wong ET (2005) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 64:934
5. Enting RH, Demopoulos A, DeAngelis LM, Abrey LE (2004) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 63:901-903
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003
7. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280
8. Möllemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379-385
9. Mikeska T, Bock C, El-Maarri O, Hübner A, Ehrentraut D, Schramm J, Felsberg J, Kahl P, Büttner R, Pietsch T, Waha A (2007) Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9:368-381
10. Herrlinger U, Küker W, Platten M, Dichgans J, Weller M (2002) First-line therapy with temozolomide induces regression of primary CNS lymphoma. Neurology 58:1573-1574
11. Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J, Frenay M, De Beule N, Delattre JY, Baron B, European Organization for Research, Treatment of Cancer Brain Tumor Group (2003) Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 21:2726-2731
12. Illerhaus G, Marks R, Müller F, Ihorst G, Feuerhake F, Deckert M, Ostertag C, Finke J (2009) High-dose methotrexate combined with procarbazine and CCNU for primary CNS lymphoma in the elderly: results of a prospective pilot and phase II study. Ann Oncol 20:319-325
13. Omuro AM, Taillandier L, Chinot O, Carnin C, Barrie M, Hoang- Xuan K (2007) Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 85:207-211